Data on monoclonal antibodies reported by researchers at Genentech, Inc.
2007 NOV 21 -- According to a study from the United States, "Background Although combination treatment with bevacizumab (humanized monoclonal antibody against vascular endothelial growth factor) and chemotherapy improves survival of patients with various metastatic carcinomas, an increased risk of arterial thromboembolic events has been observed in some trials, We characterized this risk by performing post hoc analyses of randomized controlled trials that evaluated combination treatment with bevacizumab and chemotherapy versus chemotherapy alone. Low-dose aspirin was permitted in these trials, and its safety was also analyzed." "Methods Data were pooled from five randomized controlled trials that included a total of 1745 patients with metastatic colorectal, breast, or non-small-cell lung carcinoma. The risk of an arterial or venous thromboembolic event was assessed by simple incidence rates, rates per 100 person-years, and/or hazard ratios (HRs). The association between patient characteristics and risk of an arterial thromboembolic event was investigated primarily by Cox proportional hazards regression. The relationship between low-dose aspirin and bleeding was explored by incidence rates and rates per 100 person-years. Results Combined treatment with bevacizumab and chemotherapy, compared with chemotherapy alone, was associated with increased risk for an arterial thromboembolic event (HR = 2.0, 95% confidence interval [CI] = 1.05 to 3.75; P = .031) but not for a venous thromboembolic event (HR = 0.89, 95% CI = 0.66 to 1.20; P =.44). The absolute rate of developing an arterial thromboembolism was 5.5 events per 100 person-years for those receiving combination therapy and 3.1 events per 100 person-years for those receiving chemotherapy alone (ratio = 1.8, 95% CI = 0.94 to 3.33; P = .076). Development of an arterial thromboembolic event was associated with a prior arterial thromboembolic event (P <.001) or age of 65 years or older (P = .01). Baseline or on-study aspirin use was associated with modest increases in grade 3 and 4 bleeding events in both treatment groups, from 3.6% to 4.7% for bevacizumab-treated patients and from 1.7% to 2.2% for control subjects," wrote F.A. Scappaticci and colleagues, Genentech, Inc. The researchers concluded: "Conclusions Combination treatment with bevacizumab and chemotherapy, compared with chemotherapy alone, was associated with an increased risk of arterial thromboembolism but not venous thromboembolism." Scappaticci and colleagues published the results of their research in the Journal of the National Cancer Institute (Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. Journal of the National Cancer Institute, 2007;99(16):1232-1239). For additional information, contact F.A. Scappaticci, Genentech Inc., 455 E Grand Avenue, San Francisco, CA 94080, USA. The publisher of the Journal of the National Cancer Institute can be contacted at: Oxford University Press Inc., Journals Dept., 2001 Evans Rd., Cary, NC 27513, USA. Keywords: United States, San Francisco, Bevacizumab, Biotechnology, Drugs, Monoclonal Antibodies, Pharmaceuticals, Therapy, Treatment, Genentech, Inc. This article was prepared by Healthcare Finance, Tax & Law Week editors from staff and other reports. Copyright 2007, Healthcare Finance, Tax & Law Week via NewsRx.com.
|
